Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 4, 2011, Pages 300-305

  Berg, Daniela ^a   Langer, Rupert ^a   Tran, Kai ^a   Walch, Axel ^b   Schuster, Tibor ^a   Bronger, Holger ^a   Becker, Karl Friedrich ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

core biopsy; formalin fixed and paraffin embedded tissue; human epidermal growth factor receptor 2; immunohistochemsitry; reverse phase protein array; surgical specimen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FORMALDEHYDE; PARAFFIN; PROGESTERONE RECEPTOR;

ARTICLE; BIOPSY; BREAST CANCER; CLINICAL ARTICLE; COMPARATIVE STUDY; CORE BIOPSY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN MICROARRAY;

BIOPSY; BREAST NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; ESTROGEN RECEPTOR ALPHA; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, HUMAN; MASTECTOMY; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959321895     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182054f9f     Document Type: Article

References (34)

1. Abraham G, Kowalczyk A, Loi S, et al. Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. BMC Bioinformatics. 2010;11:277.
2. Rose C, Thorpe SM, Lober J, et al. Therapeutic effect of tamoxifen related to estrogen receptor level. Recent Results Cancer Res. 1980;71:134-141. (Pubitemid 10121392)
3. Stierer M, Rosen H, Weber R, et al. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg. 1993;218:13-21.
4. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991; 9:1283-1297.
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science. 1987;235:177-182. (Pubitemid 17231334)
6. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712. (Pubitemid 19147683)
7. Marty MCF, Cognetti F, Maraninchi D, et al. Randomized phase II trail of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: M77001 study group. J Clin Oncol. 2005;23:4265-4274. (Pubitemid 46207001)
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. (Pubitemid 41464705)
9. Arnedos M, Nerurkar A, Osin P, et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009;20:1948-1952.
10. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481. (Pubitemid 29220854)
11. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105. (Pubitemid 34791099)
12. Wulfkuhle JD, Edmiston KH, Liotta LA, et al. Technology insight: pharmacoproteomics for cancer - promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. 2006;3: 256-268. (Pubitemid 43731111)
13. Grubb RL, Calvert VS, Wulkuhle JD, et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics. 2003;3:2142-2146. (Pubitemid 37414080)
14. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20:1981-1989. (Pubitemid 32458030)
15. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003;3: 317-325. (Pubitemid 38340301)
16. Cavaliere A, Sidoni A, Scheibel M, et al. Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett. 2005;218:117-121.
17. Park SY, Kim KS, Lee TG, et al. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. Am J Surg. 2009;197:266-269.
18. Sutela A, Vanninen R, Sudah M, et al. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Acta Oncol. 2008;47:38-46.
19. Usami S, Moriya T, Amari M, et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol. 2007;37:250-255. (Pubitemid 47090677)
20. Becker KF, Schott C, Hipp S, et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol. 2007;211: 370-378. (Pubitemid 46172713)
21. Berg D, Hipp S, Malinowsky K, et al. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur J Cancer. 2010;46:47-55.
22. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
23. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987;8:138-140.
24. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
25. Di Loreto C, Puglisi F, Rimondi G, et al. Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur J Cancer. 1996;32A:1693-1700. (Pubitemid 26306879)
26. Connor CS, Tawfik OW, Joyce AJ, et al. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg. 2002;184:322-324. (Pubitemid 35287351)
27. Taucher S, Rudas M, Mader RM, et al. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr. 2004; 116:26-31. (Pubitemid 38313560)
28. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23:5148-5154. (Pubitemid 46224023)
29. Badoual C, Maruani A, Ghorra C, et al. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions. Breast. 2005;14:22-27. (Pubitemid 40197823)
30. Al Sarakbi W, Salhab M, Thomas V, et al. Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surg Oncol. 2005;2:15.
31. Hodi Z, Chakrabarti J, Lee AH, et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol. 2007;60:299-302. (Pubitemid 46447747)
32. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast. 2006;15: 167-172.
33. Tamaki K, Sasano H, Ishida T, et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci. 2010;101:2074-2079.
34. Malinowsky K, Wolff C, Ergin B, et al. Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. J Cell Physiol. 2010;225:364-370. [Epub ahead of print].